Windtree Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Windtree Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Windtree Therapeutics Inc Strategy Report
- Understand Windtree Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Windtree Therapeutics Inc (Windtree Therapeutics) is a clinical-stage biopharmaceutical company that focuses on developing its drug product candidates for the treatment of pulmonary and cardiovascular diseases. The company’s lead development programs are istaroxime, for treating acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and lyophilized KL4 surfactant intratracheal suspension, both for treating respiratory distress syndrome (RDS) in premature infants; KL4 surfactant for the treatment of lung injury effected by sever Covid-19 infection; oral SERCA2a activators for chronic heart failure; Eleison Oncology for ADS; CVI-IST2 for oral heart failure and rostafuroxin for treating genetically associated hypertension. The company benefits from the proprietary technology platform Aerosol Delivery System (ADS) with pulmonary surfactants or in combination with other products to treat pediatric and adult respiratory disorders. The company operates in Taiwan, Milan, Taipei, and Italy. Windtree Therapeutics is headquartered in Warrington, Pennsylvania, the US.
Headquarters
United States of America
Address
2600 Kelly Rd Ste 100, Warrington, Pennsylvania, 18976-3652
Website
windtreetx.com
Telephone
1 215 4889300
No of Employees
20
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
WINT (NASD)
EPS
XYZ
Net Income (2021)
XYZ
42%
(2021 vs 2020)
Market Cap*
$3.1M
Net Profit Margin (0 vs)
XYZ
0.0%
(2021 vs 2020)
* As of and is in US$
Windtree Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | WINDTREE |
| CV-IST2- Oral Heart Failure | SURFAXIN |
| Istaroxime- Acute Heart Failure and Cardiogenic Shock | SRT |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company signed an agreement to acquire the assets from Varian Biopharmaceuticals, Inc. |
| 2022 | Contracts/Agreements | In August, the company entered into an agreement with Lee’s Pharmaceutical (HK) Limited and its affiliate Zhaoke Pharmaceutical (Hefei) Co. Ltd. for the development and commercialization of its acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF for the treatment of preterm infants with respiratory distress syndrome and other potential applications. |
| 2021 | Regulatory Approval | In April, the company announced it filing a track one prioritized application with the United States Patent and Trademark Office (USPTO) for the new istaroxime patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT). |
Competitor Comparison
| Key Parameters | Windtree Therapeutics Inc | Chiesi Farmaceutici SpA | Cumberland Pharmaceuticals Inc | U.S. Stem Cell Inc | RespireRx Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Italy | United States of America | United States of America | United States of America |
| City | Warrington | Parma | Nashville | Sunrise | Glen Rock |
| State/Province | Pennsylvania | Emilia-Romagna | Tennessee | Florida | New Jersey |
| No. of Employees | 20 | 6,500 | 91 | 3 | 2 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Huang | Chairman | Executive Board | 2019 | 56 |
| Craig E. Fraser | Chief Executive Officer; President; Director | Executive Board | 2016 | 58 |
| Eric Curtis | Chief Operating Officer; Senior Vice President | Senior Management | 2020 | 55 |
| Steven G. Simonson, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2014 | 64 |
| John Tattory | Chief Financial Officer - Interim | Senior Management | 2023 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward